

Closing the gap: Uncovering unmet needs in psoriasis care

Psoriasis (PsO) is a prevalent, chronic immune-mediated disease resulting in overproduction of skin cells, which causes inflamed, scaly plaques that may be itchy or painful¹.

One icon = 6.25 million individuals worldwide*





Methods⁴

We are asking 4,500 total survey participants in 11 countries...



2,900 adults



1,200 HCPs


(Dermatologists and advanced practice providers)



200 adolescents



200 caregivers



... How does psoriasis impact patients' lives and what would an ideal psoriasis treatment look like?


Interim results from the ENCOMPASS-SI sub-study focused on US-based participants



A web-based quantitative survey of 393 adult patients with psoriasis and 200 HCPs



A subset participated in in-depth qualitative interviews to provide deeper context to survey findings



ENCOMPASS explores:



Treatment selection considerations

- ✓ Therapy advantages/disadvantages
- Perceived treatment burden
- ✓ Adherence challenges
- Convenience factors
- ✓ HCP communication & engagement
- Past treatment experience and treatment goals




PsO symptoms experience and its daily impact on life

- Skin symptoms (itchy, sore, painful, stinging)
- Emotional impact (embarrassment, worry, self-consciousness)
- Social challenges (bullying, exclusion, relationships)
- Daily life interference (activities, chores, work/school)
- Clothing limitations
- ✓ Itch and sleep disturbance

Through quantitative surveys and in-depth qualitative interviews, findings explore key aspects such as treatment experience, satisfaction, and patient and HCP perceptions of different therapy.


Initial Results from U.S. Market³

Both patients and HCPs prefer oral treatments*



^{*}Patients were provided three options: oral, topical, and injectable. HCPs were provided four options: oral, topical, and injectable, and "mode of administration doesn't matter to me." The last option accounts for 11%.

The current treatment mix does not align to patient preference




^{*}Patients were asked which prescribed treatments they were currently using to treat their PsO. Responses were not mutually exclusive.



of patients currently receiving new oral treatment

Willingness to try a new pill




Top reported clinical disadvantages of injectables

66%


"They (my patients) don't like the method of administration" 47.5%

"Treatments require monitoring and follow-up visits" Newer oral treatments also pose concerns:



AN UNMET NEED REMAINS...

... for oral psoriasis treatments that deliver high levels of skin clearance and have favorable safety profiles —thus allowing patients and HCPs to achieve optimal outcomes without compromising efficacy, safety, and preference for oral administration.



¹National Psoriasis Foundation. About Psoriasis. Available at: https://www.psoriasis.org/about-psoriasis. Accessed June 2025. 2 National Psoriasis Foundation. Psoriasis Statistics. Available at: https://www.psoriasis.org/content/statistics. Accessed June 2025.
³Data on File. Janssen. Decision Resources & Internal Claims Research. Truven Health Analytics Data.
⁴Stein Gold, L et al. "Unmet Needs of Adults with Psoriasis and Clinicians Treating Psoriasis in the US" AAD Innovation Academy 2025. Abstract #70041.

